scholarly journals Apolipoprotein E interacts with amyloid-β oligomers via positively cooperative multivalent binding

2018 ◽  
Author(s):  
S. Ghosh ◽  
T. B. Sil ◽  
S. Dolai ◽  
K. Garai

AbstractInteraction of apolipoprotein E (apoE) isoforms with amyloid-β (Aβ) peptides is considered a critical determinant of the progression of Alzheimer’s disease. However, molecular mechanism of the apoE-Aβ interaction is poorly understood. Here we characterize the nature of the apoE-Aβ complexes and identify the region of apoE that interacts with Aβ. We have prepared three distinct fragments of apoE4, viz., the N-terminal fragment (NTF), hinge domain fragment (HDF) and C-terminal fragment (CTF) to compare its interactions with Aβ. Kinetics of aggregation of Aβ is delayed dramatically in presence of low, substoichiometric concentrations of both NTF and CTF in lipid-free, as well as, in lipidated forms. Effect of HDF is found to be small. Strong inhibition by NTF and CTF at substoichiometric concentrations indicate interactions with the ‘intermediates’ or the oligomers of Aβ. Kinetics of Forster Resonance Energy Transfer (FRET) between full-length apoE4 labeled with EDANS at positions 62, 139, 210, 247, and 276 and tetramethylrhodamine (TMR)-labeled Aβ further support involvement of multiple regions of apoE in the interactions. Since the interactions involve intermediates of Aβ quantitative evaluation of the binding affinities are not feasible. Hence we employed a competitive binding assay to examine whether the N- and C-terminal domains interact cooperatively. Addition of unlabeled full-length apoE eliminates the FRET between EDANS-NTF + EDANS-CTF and TMR-Aβ almost completely but not vice versa. Furthermore, full-length apoE but not the equimolar mixture of the fragments could displace the already bound EDANS-apoE molecules from the complexes. Therefore, binding affinity of the Aβ oligomers to the intact full-length apoE is much higher than the affinity to the domains when mixed together as fragments. Thus, our results indicate that apoE-Aβ complex formation is mediated by positively cooperative multivalent binding between the multiple sites on apoE and the oligomeric forms of Aβ.

2017 ◽  
Vol 8 (7) ◽  
pp. 4996-5004 ◽  
Author(s):  
C. Dammers ◽  
M. Schwarten ◽  
A. K. Buell ◽  
D. Willbold

Fibrillary and monomeric pyroglutamate-modified amyloid-β(3-42) accelerates all individual reaction steps of full-length amyloid-β(1-42) and act as a subsequent seeding species.


Biochemistry ◽  
2014 ◽  
Vol 53 (40) ◽  
pp. 6323-6331 ◽  
Author(s):  
Kanchan Garai ◽  
Philip B. Verghese ◽  
Berevan Baban ◽  
David M. Holtzman ◽  
Carl Frieden

2019 ◽  
Vol 26 (7) ◽  
pp. 502-511 ◽  
Author(s):  
Deborah L. Heyl ◽  
Brandon Iwaniec ◽  
Daniel Esckilsen ◽  
Deanna Price ◽  
Prathyusha Guttikonda ◽  
...  

Background: Amyloid fibrils in Alzheimer’s disease are composed of amyloid-β (Aβ) peptides of variant lengths. Humanin (HN), a 24 amino acid residue neuroprotective peptide, is known to interact with the predominant Aβ isoform in the brain, Aβ (1-40). Methods: Here, we constructed smaller segments of Aβ and HN and identified residues in HN important for both HN-HN and HN-Aβ interactions. Peptides corresponding to amino acid residues 5- 15 of HN, HN (5-15), HN (5-15, L11S), where Leu11 was replaced with Ser, and residues 17-28 of Aβ, Aβ (17-28), were synthesized and tested for their ability to block formation of the complex between HN and Aβ (1-40). Results: Co-immunoprecipitation and binding kinetics showed that HN (5-15) was more efficient at blocking the complex between HN and Aβ (1-40) than either HN (5-15, L11S) or Aβ (17-28). Binding kinetics of these smaller peptides with either full-length HN or Aβ (1-40) showed that HN (5- 15) was able to bind either Aβ (1-40) or HN more efficiently than HN (5-15, L11S) or Aβ (17-28). Compared to full-length HN, however, HN (5-15) bound Aβ (1-40) with a weaker affinity suggesting that while HN (5-15) binds Aβ, other residues in the full length HN peptide are necessary for maximum interactions. Conclusion: L11 was more important for interactions with Aβ (1-40) than with HN. Aβ (17-28) was relatively ineffective at binding to either Aβ (1-40) or HN. Moreover, HN, and the smaller HN (5-15), HN (5-15 L11S), and Aβ (17-28) peptides, had different effects on regulating Aβ (1-40) aggregation kinetics.


2020 ◽  
Vol 21 (3) ◽  
pp. 802 ◽  
Author(s):  
Shin Bi Oh ◽  
Jung Ah Kim ◽  
SuJi Park ◽  
Joo-Yong Lee

Zinc and apolipoprotein E (apoE) are reportedly involved in the pathology of Alzheimer’s disease. To investigate the associative interaction among zinc, apoE, and amyloid-β (Aβ) and its role in amyloid pathogenesis, we performed various biochemical and immunoreactive analyses using brain tissues of Tg2576 mice and synthetic Aβ and apoE peptides. On amyloid plaques or in brain lysates of Tg2576 mice, apoE and Aβ immunoreactivities increased after zinc chelation and were restored by its subsequent replacement. Zinc depletion dissociated apoE/Aβ complexes or larger-molecular sizes of Aβ oligomers/aggregates into smaller-molecular sizes of apoE and/or Aβ monomers/complexes. In the presence of zinc, synthetic apoE and/or Aβ peptides aggregated into larger-molecular sizes of oligomers or complexes. Endogenous proteases or plasmin in brain lysates degraded apoE and/or Aβ complexes, and their proteolytic activity increased with zinc depletion. These biochemical findings suggest that zinc associates with apoE and Aβ to encourage the formation of apoE/Aβ complexes or large aggregates, raising the deposition of zinc-rich amyloid plaques. In turn, the presence of abundant zinc around and within apoE/Aβ complexes may block the access or activity of Aβ-degrading antibodies or proteases. These results support the plausibility of chelation strategy aiming at reducing amyloid pathology in Alzheimer’s disease.


2018 ◽  
Vol 15 (6) ◽  
pp. 504-510 ◽  
Author(s):  
Sara Sanz-Blasco ◽  
Maria Calvo-Rodríguez ◽  
Erica Caballero ◽  
Monica Garcia-Durillo ◽  
Lucia Nunez ◽  
...  

Objectives: Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer's disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ). Methods: We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and Rflurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death. Results: Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.


2021 ◽  
Vol 22 (3) ◽  
pp. 1225
Author(s):  
Ziao Fu ◽  
William E. Van Nostrand ◽  
Steven O. Smith

The amyloid-β (Aβ) peptides are associated with two prominent diseases in the brain, Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA). Aβ42 is the dominant component of cored parenchymal plaques associated with AD, while Aβ40 is the predominant component of vascular amyloid associated with CAA. There are familial CAA mutations at positions Glu22 and Asp23 that lead to aggressive Aβ aggregation, drive vascular amyloid deposition and result in degradation of vascular membranes. In this study, we compared the transition of the monomeric Aβ40-WT peptide into soluble oligomers and fibrils with the corresponding transitions of the Aβ40-Dutch (E22Q), Aβ40-Iowa (D23N) and Aβ40-Dutch, Iowa (E22Q, D23N) mutants. FTIR measurements show that in a fashion similar to Aβ40-WT, the familial CAA mutants form transient intermediates with anti-parallel β-structure. This structure appears before the formation of cross-β-sheet fibrils as determined by thioflavin T fluorescence and circular dichroism spectroscopy and occurs when AFM images reveal the presence of soluble oligomers and protofibrils. Although the anti-parallel β-hairpin is a common intermediate on the pathway to Aβ fibrils for the four peptides studied, the rate of conversion to cross-β-sheet fibril structure differs for each.


2021 ◽  
Vol 1 (1) ◽  
pp. 20-21
Author(s):  
Fanjie Meng ◽  
Hoi Sung Chung
Keyword(s):  

Author(s):  
Valery N. Mukhin ◽  
Ivan R. Borovets ◽  
Vadim V. Sizov ◽  
Konstantin I. Pavlov ◽  
Victor M. Klimenko

Sign in / Sign up

Export Citation Format

Share Document